Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis

Nawrocki, Shiri; Cha, Jisun

doi:10.1016/j.jaad.2019.11.042

Cited by 51 publications

(54 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diagnosis of IH can only be considered after secondary causes of excessive sweating have been excluded such as drugs, toxins, and systemic diseases (endocrine, neurologic or metabolic conditions, malignancies) [14]. In 90% of IH cases, commonly affected areas include the axillae, palms, soles, or craniofacial regions [15].…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…Although the risk of AEs from the BTX-A injections was increased compared to the placebo, the events were mild and brief. The safety of BTX-A was also proven during the treatment of other diseases, such as chronic migraine, primary hyperhidrosis, nocturnal molars, and dystonia (25)(26)(27)(28). The long-term effect of a single dose may be conducive to improving compliance and cost-effectiveness.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Qian

Shao

Lenahan³

et al. 2020

Front. Psychiatry

View full text Add to dashboard Cite

Background: Major depressive disorder (MDD) is a serious mental disorder that represents a substantial public health problem. Several trials have been undertaken to investigate the role of botulinum toxin type A (BTX-A) in the treatment of MDD, but the conclusions were controversial. To examine the efficacy and safety of BTX-A vs. placebo on patients with a clinical diagnosis of MDD, we conducted this systematic review and meta-analysis.Methods: A systematic search was conducted for all relevant randomized controlled trials (RCTs) in PubMed and Web of Science from inception to June 17, 2020. All published studies that investigated the efficacy and safety of BTX-A injections on patients with a clinical diagnosis of MDD were included. The overall effect size was summarized using a random-effects meta-analysis model. The primary outcomes of the present meta-analysis were the changes in depressive rating scale at week 6 after BTX-A injection compared with placebo. The safety of BTX-A injections also was assessed.Results: Five RCTs with a total of 417 participants (189 patients in the BTX-A group, 228 patients in placebo group) were eligible in this meta-analysis. The results indicated an overall positive effect of BTX-A injections for reducing the depressive symptoms of patients with MDD (Hedges' g, −0.82; 95% CI, −1.38 to −0.27) with large effect size. Differences are likely explained by the dose of BTX-As and the gender of the participants. Our findings also highlighted that BTX-A injections were generally well-tolerated, with only mild and temporary adverse events reported.Conclusions: The present meta-analysis provides evidence that BTX-A injections are associated with a statistically significant improvement in depressive symptoms. BTX-A injections are generally safe and may provide a new, alternative option for the treatment of depression.

show abstract

“…It severely affects the patient's daily activities due to the social and professional disadvantages. HH can be primary, which accounts for 93% of HH patients and presents before 25 years of age, or secondary to an underlying medical condition or use of medications [1]. Whereas primary HH is usually focal, symmetric and mostly affects axillae, palms, soles, and craniofacial region, secondary HH tends to be asymmetric or generalized and requires a complete study to exclude infection, diabetes mellitus, Parkinson's disease, hyperthyroidism, anxiety, phaeochromocytoma, and menopause [2,3].…”

Section: Introductionmentioning

confidence: 99%

“…However, efficiency is variable, and none of them is exempt from side effects. In this context, Botulinum toxin A (BTX-A) injection has emerged as a new therapeutic approach for the management of focal HH with higher satisfaction rates than with other treatment methods [1,4,5]. We focus on the treatment of perianal HH with injectable BTX for which little scientific information is available in medical literature.…”

Section: Introductionmentioning

confidence: 99%

Perianal Hyperhidrosis Successfully Treated with Botulinum Toxin A

Cura¹,

Monfort²,

Sancho³

et al. 2021

Skin Appendage Disord

View full text Add to dashboard Cite

Perianal hyperhidrosis (HH) is a rare form of primary focal HH and may become a major problem for the patient with a significant psychosocial burden and negative impact on the quality of life. Botulinum toxin injections are widely used as a second-line treatment option for axillary, palmar, and plantar HH with a good safety profile. Herein, we present a case of primary perianal HH successfully treated with Botulinum toxin A at a dose higher than that previously reported in literature, with a longer response, a higher degree of satisfaction, and no adverse effects. Moreover, we review the main aspects of the perianal anatomy that are essential to carry out the technique correctly and make dermatologists achieve expertise with the procedure.

show abstract

Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis

Cited by 51 publications

References 118 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Perianal Hyperhidrosis Successfully Treated with Botulinum Toxin A

Contact Info

Product

Resources

About